Depomed Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy
May 9, 2016 7:37 AM EDTMizuho Securities upgraded DepoMed Inc (NASDAQ: DEPO) from Neutral to Buy with a price target of $19.00 (from $18.00), on increased takeout probability.
Analyst Irina Koffler commented, "DEPO posted unimpressive numbers in 1Q:16 and shares got dragged down with the group on Friday.... More
DepoMed (DEPO) PT Lowered to $21 at Piper Jaffray
May 6, 2016 9:09 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on DepoMed Inc (NASDAQ: DEPO) to $21.00 (from $23.00) and reiterated a Overweight rating following Q1 results.
Amsellem commented, "Depomed reported adjusted diluted EPS of $0.12 on revenues of $105M, versus Street estimates of $0.17 and $107M, respectively... More
